Home What is Buprenorphine? DATA Physician Locator DATA 2000 FAQs Notices Links En Español
Physician Waiver Qualifications Waiver Notification Form Upcoming Trainings Waived Physician WebBoard Update Physician Contact Information Model State Medical Board Policy
Buprenorphine Summits Articles SAMHSA Reports Other Gov't Reports
Nurses Guide to Buprenorphine
Notice of Inspection of Controlled Premises
A Notice of Inspection of Controlled Premises (Form DEA-82) must be signed prior to a DATA 2000 inspection. It includes a statement of physicians' rights as well as an authorization to inspect the controlled premises. Use this link to go to a copy of a blank notice form.Generic Subutex Approved
October 8, 2009Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Buprenorphine HCl Sublingual Tablets, 2mg and 8mg, by the U.S. Food and Drug Administration. The product is available in bottles of 30 for immediate shipment to wholesalers and pharmacies nationwide. Roxane Laboratories' Buprenorphine HCl Sublingual Tablets are AB rated to Subutex® (buprenorphine HCl) tablets. Annual sales of Subutex® are approximately $67.7 million.SAMHSA Issues Nationwide Public Health Alert Concerning Life Threatening Risk Posed by Cocaine Laced with Veterinary Anti-Parasite Drug
September 18, 2009SAMHSA is alerting medical professionals, substance abuse treatment centers, and other public health authorities about the risk that substantial levels of cocaine may be adulterated with levamisolea veterinary anti-parasitic drug. As of this date, there have been approximately 20 confirmed or probable cases of agranulocytosis (a serious, sometimes fatal blood disorder), including two deaths, associated with cocaine adulterated with levamisole. The number of reported cases is expected to increase as information about cocaine adulterated with levamisole is disseminated. Use this link to go to the letter.SAMHSA and DEA Issue Letter on Prescribing Suboxone/Subutex in Opioid Treatment Programs
April 27, 2009This letter sets forth the current Federal regulations regarding a physician's authority, while employed by an Opioid Treatment Program (OTP) certified by SAMHSA and registered with the Drug Enforcement Administration (DEA) as a Narcotic Treatment Program (NTP) (hereinafter OTP), to prescribe, write orders for, or dispense Suboxone® or Subutex® to patients for addiction/dependence treatment under the provisions of the Drug Addiction Treatment Act of 2000 (DATA 2000). Use this link to go to the letter.
Home | Accessibility | Privacy | Disclaimer | SAMHSA
Department of Health & Human Services | USA.gov
* Adobe™ PDF formatted files require the Adobe™ Reader to properly read them. Use this link to download this FREE program.